Drug Eluting Stent (DES) Market Size, Share, Competitive Insights, Growth Dynamics, and Forecast Report 2032

The drug-eluting stent (DES) market focuses on coronary stents coated with medications that are slowly released to prevent the re-narrowing of arteries after angioplasty. These stents combine mechanical support to keep blood vessels open with localized drug delivery to reduce restenosis and the need for repeat procedures. Market growth is driven by the rising global incidence of cardiovascular diseases, increasing adoption of minimally invasive procedures, an aging population, and continuous improvements in stent design and drug coatings. New-generation DES feature thinner struts, biodegradable polymers, and improved biocompatibility for better patient outcomes. Hospitals and specialty cardiac centers are the primary end users. North America currently leads the market thanks to advanced healthcare infrastructure, high rates of coronary interventions, and rapid approval of innovative products, while Asia-Pacific is expected to see the fastest growth due to expanding healthcare access, a growing patient base, and rising lifestyle-related heart conditions. Key challenges include high procedure costs, the risk of late thrombosis, and strict regulatory requirements for new stent technologies.

The global drug eluting stent (DES) market size was valued at USD 5.71 billion in 2018 and is projected to reach USD 13.52 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period. North America dominated the drug eluting stent market with a 30.82% share in 2018, driven by advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and strong adoption of innovative stent technologies.

Top Companies in the Market

• Boston Scientific Corporation

• Abbott

• Medtronic

• Biotronik

• Terumo Corporation

• MicroPort Scientific Corporation

• Sahajanand Medical Technologies

• Others

Key Industry Developments

• June 2021 – Abbott announced that their product line XIENCE stents have received approvals for one-month Dual Antiplatelet Therapy (DAPT) from the U.S. FDA as well as CE Mark approval in Europe as the shortest blood thinning course for patients with high bleeding risk in the U.S. region.

• January 2021 – Boston Scientific Corporation received U.S. FDA approval for their Synergy Megatron Drug Eluting Stent System, designed to treat large proximal vessels near the aorta.

Market Drivers & Restraints

Drivers

The DES market growth is being driven by several interlinked factors: rising prevalence of cardiovascular diseases (CVDs), increasing cases of coronary artery disease (CAD), arterial blockage concerns, higher occurrence of peripheral arterial disease (PAD), and growing healthcare expenditure globally.

Technological advancement also plays a major role: introduction of new designs, improved stent delivery systems, development of bioresorbable polymer coatings, ultrathin stent struts, and enhanced scaffold materials reduce risks such as restenosis and thrombosis. These innovations are pushing adoption rates higher.

Restraints

However, the market faces challenges. Frequent product recalls by key players remain a concern. Such recalls are often due to issues like partial stent deployment, leading to vessel trauma or prolongation of implant procedures, undermining confidence and increasing regulatory scrutiny.

Market Segmentation

The DES market is segmented by type, scaffold material, drug type, end-user, and region. Key segment insights include:

• By Type: Coronary stenting and peripheral stenting. Coronary stenting dominated in 2018. Peripheral stenting is expected to grow significantly during the forecast period. Coronary stenting is projected to hold about 80.1% share by 2025.

• By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, and others. Sirolimus segment expected to dominate, with newer drugs like Zotarolimus and Everolimus gaining ground due to superior clinical profiles.

• By Scaffold: Cobalt-chromium, Platinum-chromium, Nitinol, others. Cobalt-chromium is anticipated to grow fastest during forecast due to flexibility, better biocompatibility, and longer shelf-life.

• By End User: Hospitals and Specialty Clinics. Hospitals are currently the main end-users, owing to more procedures and higher infrastructure; specialty clinics may grow as interventions shift out of hospital settings.

Regional Insights

Regionally, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

• North America: Held ~30.82% of global market share in 2018. Strong growth is driven by favorable reimbursement policies, high disease prevalence, adoption of advanced stent technologies, and R&D by domestic firms.

• Europe: Expected to grow steadily, aided by CE-mark approvals of newer generation DES and advances in polymer and scaffold technologies.

• Asia Pacific: Rising burden of CVD, improving healthcare infrastructure, growing availability of advanced DES products are driving growth; China is projected to have a strong CAGR (~7.50%) during the forecast period. Japan is also focusing on adoption of cutting-edge DES in complex cardiac procedures.

Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/drug-eluting-stent-des-market-102612 

Future Market Scope

Looking ahead, the DES market’s prospects are anchored in continued innovation. Bioabsorbable polymer-based DES, ultrathin scaffolds, improved drugs with better release profiles, and enhanced delivery systems will shape the next generation of stents. As peripheral stenting becomes more prevalent, and specialty clinics begin to undertake more complex interventional procedures outside of hospital settings, those areas offer new market opportunities.

Moreover, regulatory approvals (FDA, CE Mark) for shorter dual antiplatelet therapy durations, and treatments that reduce bleeding risk without compromising efficacy, are expected to influence adoption and market dynamics significantly.

Conclusion

The global Drug Eluting Stent market is on a growth trajectory with strong demand driven by rising cardiovascular disease incidence, technological innovation, and favorable regulatory & reimbursement landscapes. Although challenges like product recalls and safety concerns persist, the future market scope remains promising especially in regions like Asia Pacific. Key players are well-positioned with continual R&D, strategic product approvals, and regulatory milestones to capitalize on this trend.

About Us:Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com